Home › Funds › Propel Bio Management, LLC › ZVRA
Propel Bio Management, LLC position in ZVRA
ZEVRA THERAPEUTICS INC · Health Care
Propel Bio Management, LLC reported holding 253,544 shares of ZVRA (ZEVRA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$3.6M, representing 1.90% of its reported portfolio and ranking #18 among its reported holdings. Propel Bio Management, LLC has disclosed ZVRA holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Propel Bio Management, LLC's ZVRA position evolved
Propel Bio Management, LLC first disclosed a stake in ZVRA in Q3 2024 at 179,874 shares (US$1.2M). The position peaked in Q2 2026 at 253,544 shares, worth US$3.6M. Across 8 filings, Propel Bio Management, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 253,544 shares valued at US$3.6M — a reduction of -28,874 shares quarter over quarter.. Notable position changes include a 29% increase in Q2 2025 (shares rose 8% over the following quarter), a 73% trim in Q4 2025 (shares rose 4% over the following quarter), a 343% increase in Q1 2026 (shares rose 54% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 179.87K | $1.25M | New |
| Q4 2024 | 179.87K | $1.50M | Hold |
| Q1 2025 | 179.87K | $1.35M | Hold |
| Q2 2025 | 231.87K | $2.04M | Add |
| Q3 2025 | 231.87K | $2.21M | Hold |
| Q4 2025 | 63.68K | $570.60K | Reduce |
| Q1 2026 | 282.42K | $2.64M | Add |
| Q2 2026 | 253.54K | $3.64M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ZVRA and 13F data
ZVRA (ZEVRA THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in ZVRA — the largest reported positions include Nantahala Capital Management, LLC (US$25.8M), 683 Capital Management, LLC (US$12.3M), KINGDON CAPITAL MANAGEMENT, L.L.C. (US$11.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ZVRA
- Nantahala Capital Management, LLC 1.80M sh · $25.78M · Q2 2026
- 683 Capital Management, LLC 855.00K sh · $12.26M · Q2 2026
- KINGDON CAPITAL MANAGEMENT, L.L.C. 775.00K sh · $11.11M · Q2 2026
- Retirement Planning Co of New England, Inc. 612.33K sh · $6.72M · Q3 2026
- Mystic Asset Management, Inc. 355.38K sh · $3.90M · Q3 2026
- Stonepine Capital Management, LLC 258.70K sh · $3.71M · Q2 2026
- Diametric Capital, LP 231.47K sh · $3.32M · Q2 2026
More on Propel Bio Management, LLC
FAQ
How long has Propel Bio Management, LLC held ZVRA?
Propel Bio Management, LLC has disclosed ZVRA holdings in 8 of the last 8 reported quarters, going back to Q3 2024.
What is Propel Bio Management, LLC's current position in ZVRA?
As of Q2 2026, Propel Bio Management, LLC holds 253.54K shares of ZVRA (ZEVRA THERAPEUTICS INC), valued at $3.64M, representing 1.90% of its reported portfolio and ranking #18.
Has Propel Bio Management, LLC been buying or selling ZVRA?
In the latest 13F filing (Q2 2026), Propel Bio Management, LLC reduced its position in ZVRA. The position peaked in Q2 2026 at 253.54K shares.
Which other funds hold ZVRA?
Other major institutional holders of ZVRA include Nantahala Capital Management, LLC, 683 Capital Management, LLC, KINGDON CAPITAL MANAGEMENT, L.L.C., among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.